ANKHD1

Across TCGA pan-cancer cohorts, ANKHD1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ANKHD1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ANKHD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ANKHD1 is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where ANKHD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKHD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.496	<.001	7	view →
HNSC	Male	All	+0.159	.017	3	view →
PDAC	Female	All	−0.429	.002	2	view →
LSCC	All	All	−0.144	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ANKHD1–CCRCC

Open the CCRCC breakdown →